Evidence & regulatory context
- Mechanism
- Neither component resolved. Noggin is a secreted BMP-antagonist glycoprotein with no ChEMBL small-molecule entity. LDN193189 (and the hyphenated form LDN-193189, an ALK2/ALK3 BMP type I receptor kinase inhibitor) returned zero ChEMBL hits under both name forms. ClinicalTrials.gov returned no trial of either agent; the single query hit (NCT04337918, nitric oxide releasing solution for COVID-19) was a spurious keyword match on 'NO' and was excluded. Recorded as zero human trials.
- Target
- Not recorded
- Injury models
- Spinal cord injury
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatSpinal cord injuryContusionSprague-DawleyFemaleAdministered during the acute phase after spinal cord injury
Model: Preclinical rat model of compressive and contusive traumatic spinal cord injury, with parallel in vitro work on neural precursor cells, oligodendrocyte precursor cells, neurons and astrocytes
Active BMP4 was robustly and transiently upregulated after injury. Acute blockade of BMPs with noggin or LDN193189 promoted oligodendrogenesis, oligodendrocyte preservation and remyelination, and markedly attenuated caspase-3 activation and lipid peroxidation. BMP4 directly induced caspase-3 mediat…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.
